The GMR Clinical Trials Unit is currently recruiting for the following clinical trials in general oncology:
PROTOCOL: HMBD-001-103 (PI: Dr Rahul Ladwa) – NOT YET RECRUITING
Protocol Title: A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination with Cetuximab, in Participants with Advanced Squamous Cell Cancers
Lay Title: Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/ – Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers
Click here for more information
protocol: GS-US-699-7184 (PI: Dr Margaret McGrath) – not yet recruiting
Protocol Title: A Phase 2 Platform Study of Novel Combination Therapies in Participants with Head and Neck Squamous Cell Carcinoma
LayTitle: Study of Novel Treatment Combination Therapies in Participants with Head and Neck Squamous Cell Carcinoma
Click here for more information
PROTOCOL: NST-628-001 (PI: Dr Victoria Atkinson)
Protocol Title: A Phase 1, open label single-arm two-part study to investigate safety, pharmacokinetics, and preliminary efficacy of pan-RAF/MEK glue NST-628 oral tablets in subjects with solid tumors harboring genetic alterations in the MAPK pathway and with other solid tumors
Lay Title: A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Click here for more information
Protocol: AMT-676-01 (PI: DR Warren Joubert)
Protocol Title: First-in-Human, Phase 1 Study of AMT-676, an Anti CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
Lay Title: AMT-676 in Patients With Advanced Solid Tumors
Click here for more infomation
PROTOCOL: MDNA11-01 (PI: DR Victoria atkinson)
Protocol Title: A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors
Lay Title: Early Phase IL-2 Superkine with and without Immune checkpoint Inhibitor in advanced solid tumour patients.